213 related articles for article (PubMed ID: 31780569)
1. Low-grade serous ovarian carcinoma: an evolution toward targeted therapy.
Voutsadakis IA
Int J Gynecol Cancer; 2020 Oct; 30(10):1619-1626. PubMed ID: 31780569
[TBL] [Abstract][Full Text] [Related]
2. Low grade serous ovarian carcinoma: identifying variations in practice patterns.
Siemon J; Gershenson DM; Slomovitz B; Schlumbrecht M
Int J Gynecol Cancer; 2019 Jan; 29(1):174-180. PubMed ID: 30640701
[TBL] [Abstract][Full Text] [Related]
3. Low-grade serous carcinoma: molecular features and contemporary treatment strategies.
Angarita AM; Cholakian D; Fader AN
Expert Rev Anticancer Ther; 2015; 15(8):893-9. PubMed ID: 26040191
[TBL] [Abstract][Full Text] [Related]
4. Low Grade Serous Ovarian Carcinoma: from the molecular characterization to the best therapeutic strategy.
Della Pepa C; Tonini G; Santini D; Losito S; Pisano C; Di Napoli M; Cecere SC; Gargiulo P; Pignata S
Cancer Treat Rev; 2015 Feb; 41(2):136-43. PubMed ID: 25573350
[TBL] [Abstract][Full Text] [Related]
5. Genomic profiling of the residual disease of advanced high-grade serous ovarian cancer after neoadjuvant chemotherapy.
Lee YJ; Kim D; Shim JE; Bae SJ; Jung YJ; Kim S; Lee H; Kim SH; Jo SB; Lee JY; Kim HS; Paik S
Int J Cancer; 2020 Apr; 146(7):1851-1861. PubMed ID: 31603993
[TBL] [Abstract][Full Text] [Related]
6. Advances in precision therapy of low-grade serous ovarian cancer: A review.
Wang Q; Cao SH; Li YY; Zhang JB; Yang XH; Zhang B
Medicine (Baltimore); 2024 Apr; 103(17):e34306. PubMed ID: 38669365
[TBL] [Abstract][Full Text] [Related]
7. The development of high-grade serous carcinoma from atypical proliferative (borderline) serous tumors and low-grade micropapillary serous carcinoma: a morphologic and molecular genetic analysis.
Dehari R; Kurman RJ; Logani S; Shih IeM
Am J Surg Pathol; 2007 Jul; 31(7):1007-12. PubMed ID: 17592266
[TBL] [Abstract][Full Text] [Related]
8. Clinicopathologic and Molecular Features of Paired Cases of Metachronous Ovarian Serous Borderline Tumor and Subsequent Serous Carcinoma.
Chui MH; Xing D; Zeppernick F; Wang ZQ; Hannibal CG; Frederiksen K; Kjaer SK; Cope L; Kurman RJ; Shih IM; Wang TL; Vang R
Am J Surg Pathol; 2019 Nov; 43(11):1462-1472. PubMed ID: 31343420
[TBL] [Abstract][Full Text] [Related]
9. Low-grade serous ovarian cancer: A review.
Kaldawy A; Segev Y; Lavie O; Auslender R; Sopik V; Narod SA
Gynecol Oncol; 2016 Nov; 143(2):433-438. PubMed ID: 27581327
[TBL] [Abstract][Full Text] [Related]
10. Morphological subtypes of ovarian carcinoma: a review with emphasis on new developments and pathogenesis.
McCluggage WG
Pathology; 2011 Aug; 43(5):420-32. PubMed ID: 21716157
[TBL] [Abstract][Full Text] [Related]
11. Molecular characterization of 103 ovarian serous and mucinous tumors.
Vereczkey I; Serester O; Dobos J; Gallai M; Szakács O; Szentirmay Z; Tóth E
Pathol Oncol Res; 2011 Sep; 17(3):551-9. PubMed ID: 21136228
[TBL] [Abstract][Full Text] [Related]
12. BRAF mutation is rare in advanced-stage low-grade ovarian serous carcinomas.
Wong KK; Tsang YT; Deavers MT; Mok SC; Zu Z; Sun C; Malpica A; Wolf JK; Lu KH; Gershenson DM
Am J Pathol; 2010 Oct; 177(4):1611-7. PubMed ID: 20802181
[TBL] [Abstract][Full Text] [Related]
13. The molecular pathology of ovarian serous borderline tumors.
Malpica A; Wong KK
Ann Oncol; 2016 Apr; 27 Suppl 1(Suppl 1):i16-i19. PubMed ID: 27141064
[TBL] [Abstract][Full Text] [Related]
14. GATA3 and stemness of high-grade serous ovarian carcinoma: novel hope for the deadliest type of ovarian cancer.
El-Arabey AA; Abdalla M; Abd-Allah AR
Hum Cell; 2020 Jul; 33(3):904-906. PubMed ID: 32388811
[No Abstract] [Full Text] [Related]
15. BRCA mutational status, initial disease presentation, and clinical outcome in high-grade serous advanced ovarian cancer: a multicenter study.
Petrillo M; Marchetti C; De Leo R; Musella A; Capoluongo E; Paris I; Benedetti Panici P; Scambia G; Fagotti A
Am J Obstet Gynecol; 2017 Sep; 217(3):334.e1-334.e9. PubMed ID: 28549976
[TBL] [Abstract][Full Text] [Related]
16. Characterization of active mitogen-activated protein kinase in ovarian serous carcinomas.
Hsu CY; Bristow R; Cha MS; Wang BG; Ho CL; Kurman RJ; Wang TL; Shih IeM
Clin Cancer Res; 2004 Oct; 10(19):6432-6. PubMed ID: 15475429
[TBL] [Abstract][Full Text] [Related]
17. Upfront debulking surgery versus interval debulking surgery for advanced tubo-ovarian high-grade serous carcinoma and diffuse peritoneal metastases treated with peritonectomy procedures plus HIPEC.
Biacchi D; Accarpio F; Ansaloni L; Macrì A; Ciardi A; Federici O; Spagnoli A; Cavaliere D; Vaira M; Sapienza P; Sammartino P
J Surg Oncol; 2019 Dec; 120(7):1208-1219. PubMed ID: 31531879
[TBL] [Abstract][Full Text] [Related]
18. Ovarian high-grade serous carcinoma with a noninvasive growth pattern simulating a serous borderline tumor.
Imamura H; Ohishi Y; Aman M; Shida K; Shinozaki T; Yasutake N; Sonoda K; Kato K; Oda Y
Hum Pathol; 2015 Oct; 46(10):1455-63. PubMed ID: 26232113
[TBL] [Abstract][Full Text] [Related]
19. Ovarian serous cystadenofibromas associated with a low-grade serous carcinoma of the peritoneum.
Hinson SA; Silva EG; Pinto K
Ann Diagn Pathol; 2013 Jun; 17(3):302-4. PubMed ID: 22921726
[TBL] [Abstract][Full Text] [Related]
20. Ovarian low-grade and high-grade serous carcinoma: pathogenesis, clinicopathologic and molecular biologic features, and diagnostic problems.
Vang R; Shih IeM; Kurman RJ
Adv Anat Pathol; 2009 Sep; 16(5):267-82. PubMed ID: 19700937
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
